哈尔滨三联药业股份有限公司 关于完成注册资本变更登记并换发营业执照的公告

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has approved a capital reduction and corresponding amendments to its articles of association, following the repurchase and cancellation of 3,000 restricted stocks from its 2022 incentive plan [1][2]. Group 1: Company Actions - The company held its fourth board meeting on September 17, 2025, and a temporary shareholders' meeting on November 24, 2025, to discuss the capital reduction [1]. - The company has completed the registration change for its capital reduction and received a new business license from the Harbin New Area Management Committee [1]. Group 2: Company Information - The registered capital of Harbin Sanlian Pharmaceutical is now RMB 316,354,550 [1]. - The company was established on June 21, 1996, and operates in various sectors including drug production, wholesale, retail, and import/export, as well as cosmetics and food production [1][2]. - The company is classified as a joint-stock company and is publicly listed [1].